Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT06960005
Enrolling by invitation Not applicable

ThyMoves: Screening and Exercise to Improve Muscle, Enhance Quality of Life, and Reduce Fall Risk in Thyroid Disease

NCT06960005 · tracked via the Priya Life Science Denmark tracker
Sponsor
Aalborg University Hospital
Phase
Not applicable
Started
2026-05-15
Last updated
2026-04-17

Condition(s) studied

Thyroid DiseaseHashimoto's ThyroiditisHyperthyreosis and GoiterHypothyroidism

Investigational drug(s) / intervention(s)

Rhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL)

Rhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL): Participants will engage in one-hour exercise sessions twice weekly for 26 weeks: one day of RYMA training and one day of ADL-based training

Study summary

Objectives:

This study aims to assess health-related quality of life (QoL) in adults with thyroid hormone disorders and identify modifiable factors to improve QoL in patients with Hashimoto's thyroiditis (HT) and multinodular toxic goiter (MNTG) through an exercise intervention.

Primary Outcome:

1\. Assess the impact of a tailored exercise program on health-related QoL in patients with HT and MNTG using the ThyPRO questionnaire.

Secondary Outcomes:

1. Evaluate the need for a screening tool to identify thyroid patients with reduced health-related QoL despite being euthyroid.
2. Assess the impact of the exercise intervention on body composition, strength, and balance function in HT and MNTG patients.

Methods:

The study is a combined cross-sectional survey and randomized controlled trial into the health related QoL in patients diagnosed with thyroid hormone disease. The cross-sectional survey will assess the overall health-related QoL in patients diagnosed with thyroid hormone disease, and help identify eligible participants for the subsequent RCT.

The RCT will evaluate the efficacy of a comprehensive screening and exercise intervention in patients ≥ 65 years diagnosed with HT or MNTG, experiencing reduced health-related QoL.

Participants:

The aim is to recruit 74 patients with HT and 74 patients with MNTG, including 50 participants from each group with reduced health-related QoL (defined in this study as ThyPRO score ≥ 30) and 24 with good health-related QoL (ThyPRO score ≤ 20)

Eligibility

Sex
FEMALE
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Women with minimum 65 years of age, with no upper limit. 2. Verified diagnosis of HT or MNTG 3. Euthyroid for at least 6 months 4. Signed the informed consent Exclusion Criteria: 1. Current participation in a structured exercise program or regular physical exercise activity above 5 hours per week 2. Previous experience with rhythm-based multitask exercise. 3. Diagnosed with significant neurological diseases (e.g. Multiple Sclerosis and myasthenia gravis), vestibular diseases or newly orthopedic surgeries (e.g. knee or hip replacement) 4. Fully dependent on walking aids 5. Active malignancy or terminal illness 6. Inability to understand Danish written and/or verbally 7. Having severely impaired cognitive function, defined as a score below 8 on the cognitive assessment "the short orientation-memory-concentration test" 8. Treatment with amiodarone within the last year 9. No changes within the last six months in medications affecting weight or body composition - e.g., GLP-1 electrolyte/fluid balance - e.g., diuretics or corticosteroid 10. Participation in other clinical intervention studies within the last six months For the cross sectional survey: Inclusion criteria: 1. Men and women with a minimum of 18 years 2. Diagnosis of primary hypothyroidism or primary hyperthyroidism

Primary outcome measure(s)

  • Change in Health-Related Quality of Life after the Exercise Intervention — 26 weeks and 52 weeks
    The Thyroid-Related Quality of Life Measure questionnaire (ThyPRO) consists of 85 items summarized into 13 scales and one single item measuring the overall impact of thyroid disease on quality of life. It includes questions on symptoms, mood, memory, tiredness, and general health. Each item is rated on a 0-4 Likert scale, with scores transformed to a 0-100 scale; higher scores indicate worse health status. The ThyPRO questionnaire wil be used to assess changes in health-related QoL at 26 weeks (post-intervention) and 52 weeks (follow-up).

Trial sites (1)

FacilityCityRegionStatus
Diabeteshuset Gistrup Denmark

More Aalborg University Hospital trials in Denmark

Characterization and Prediction of Early Onset Diabetic Peripheral Neuropathy Recruiting
Quality of Life After Transcatheter Aortic Valve Implantation Active, not recruiting
Changes in Children and Young People's Well-being and Parental Stress While Seeking Help at CAMHS in Denmark. How Does Waiting Affect CYP and Their Parents Before, During and After CAMHS Assessments. Enrolling by invitation
Revascularization of Calcified Coronary Arteries Recruiting
Treatment of Posterior Benign Paroxysmal Positional Vertigo With Mechanical Rotational Chair. Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06960005 on ClinicalTrials.gov ↗ ← All trials in Denmark